Merck

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify cervical cancer patients who may benefit from the anti-PD1 immunotherapy.

New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.

The companies plan to develop a pan-cancer CDx to measure microsatellite instability and CDx tests for tumor mutational burden and other novel biomarkers of response.

Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.

With multiple independent biomarkers, and potential combinations that may require even more subtyping, diagnostics to guide immunotherapy appears to be getting more complicated.

Theradiag's Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant drug.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.